Corvus Pharmaceuticals (CRVS) Jefferies 2024 Global Healthcare Conference summary

Pipeline and clinical progress

• Lead asset soquelitinib, an oral ITK inhibitor, is advancing to a phase III trial for relapsed T-cell lymphoma, with strong efficacy and safety data from phase I/II studies.

• Phase I trial in atopic dermatitis is enrolling, with data expected by year-end; additional immune and fibrotic diseases are targeted for future studies.

• The drug demonstrates a unique mechanism, selectively inhibiting ITK and sparing RLK, resulting in Th1 skewing and suppression of Th2/Th17 pathways.

• Durable responses, including complete remissions, have been observed in heavily pretreated lymphoma patients, with minimal side effects.

• A phase I study in renal cell cancer is planned, leveraging the drug’s immunomodulatory effects in solid tumors.

Market opportunity and competitive landscape

• T-cell lymphoma represents a significant unmet need, with current therapies offering limited efficacy and high toxicity.

• The addressable market is estimated at $800 million for a subset, with potential to expand several-fold as the drug targets broader indications.

• Soquelitinib’s oral administration and safety profile differentiate it from existing chemotherapies and biologics.

• The atopic dermatitis market is competitive, but the drug’s broad cytokine inhibition and safety may offer advantages over JAK inhibitors and biologics.

• Strong patent protection extends to 2037, with additional applications covering methods and monitoring.

Financial position and strategic outlook

• Recent equity financing raised $30.6 million, extending runway into early 2026; warrants could provide an additional $60 million.

• The company is pursuing partnering strategies to leverage its platform across multiple indications.

• Experienced leadership team with a track record of paradigm-shifting drug development.

• No direct competition in ITK inhibition for the lead indications, with a first-mover advantage reminiscent of past industry successes.

• Ongoing trials and proof-of-concept data in immune diseases could unlock further value and expansion opportunities.